Segment Information (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Reconciliation to the Consolidated Net Loss

A reconciliation to the consolidated net loss for the years ended December 31, 2024, 2023 and 2022 is included at the bottom of the table below.

	Year Ended December 31,
	2024			2023			2022
	(in thousands)
Revenues	$	41,243		$	86,455		$	7,686
Cost of revenues		9,444			2,159			813
Program expenses (1)
ZULRESSO		5,101			4,395			17,083
zuranolone (ZURZUVAE)		30,482			94,174			68,155
SAGE-324		10,173			16,574			14,646
dalzanemdor (SAGE-718)		58,248			56,536			50,584
Other research and development programs		33,277			52,975			49,750
Non-program expenses (2)		85,405			113,388			96,825
People and staff augmentation		165,158			220,188			195,214
Restructuring		21,854			33,386			—
Other segment items (3)		22,767			34,169			47,400
Net loss	$	(400,666	)	$	(541,489	)	$	(532,784	)
(1) Includes external research and development, and selling, general and administrative expenses.
(2) Includes information technology, infrastructure, facilities, legal, commercial data and systems,
chemistry platform, intellectual property, and other general and administrative expense.
(3) Includes stock-based compensation expense, interest income, and other (income) expense.